DXCM
DexCom, Inc. · NASDAQ
- Sector Health Technology
- Industry Medical Specialties
- Website dexcom.com
- Employees(FY) 7500
- ISIN US2521311074
Performance
+1.21%
1W
+3.95%
1M
-3.15%
3M
-42.72%
6M
-39.37%
YTD
-30.95%
1Y
Profile
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.
Technical Analysis of DXCM 2024-11-20
Technical Scores and Rating
Moving Average Score
Oscillator Score
Technical Rating
Recent News & Updates
- 2024-11-20 06:00
- 2024-11-19 12:50
- 2024-11-19 11:15
Dexcom invests $75m in ŌURA to forge partnership(Medical Device Network)
- 2024-11-19 08:45
- 2024-11-19 06:00
Dexcom and ŌURA Announce Strategic Partnership(Business Wire)
- 2024-11-18 18:51
- 2024-11-18 17:00
- 2024-11-18 17:00
Dexcom and URA Announce Strategic Partnership(Businesswire)
- 2024-11-18 17:00
Dexcom and OURA Announce Strategic Partnership(Businesswire)
- 2024-11-18 16:20
- 2024-11-15 12:12
- 2024-11-14 06:00
- 2024-11-13 17:00
- 2024-11-12 19:00
DXCM: Raising target price to $56.00(Argus Research)
- 2024-11-12 19:00
DXCM: Raising target price to $59.00(Argus Research)
- 2024-11-12 03:43
- 2024-11-08 10:15
- 2024-11-05 19:00
DXCM: Lowering target price to $54.00(Argus Research)
- 2024-11-05 19:00
DXCM: Lowering target price to $55.00(Argus Research)
- 2024-11-01 12:29
DexCom (DXCM) Fell Due to an Uncharacteristic Earnings Miss(Insider Monkey)
- 2024-10-30 15:02
- 2024-10-30 12:44
Here’s Why DexCom (DXCM) Detracted in Q3(Insider Monkey)
- 2024-10-30 09:14
Multiple Headwinds Dragged DexCom (DXCM) in Q3(Insider Monkey)
- 2024-10-28 09:50
- 2024-10-28 09:00
- 2024-10-26 08:21
DexCom Third Quarter 2024 Earnings: EPS Misses Expectations(Simply Wall St.)
- 2024-10-26 04:26
- 2024-10-26 04:02
Decoding DexCom Inc (DXCM): A Strategic SWOT Insight(GuruFocus.com)
- 2024-10-25 23:47
Dexcom chief commercial officer to retire(Yahoo Finance)
- 2024-10-25 21:25
Analyst Report: DexCom, Inc.(Yahoo Finance)
Page 1 of 10
previousnext
Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.